Clinical Trial Update: Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial updating the effects of tiotropium (Spiriva) on exercise tolerance in patients with chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• tiotropium (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED